Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12586297 | 0.81 | HSD17B10 (0.47) | HSD17B10L3MBTL1HSD11B1KMT2AEPHX2 | |
| SCHEMBL12586243 | 0.78 | HSD11B1 (0.49) | HSD17B10L3MBTL1HSD11B1KMT2AEPHX2 | |
| SCHEMBL12586492 | 0.77 | HSD17B10 (0.46) | HSD17B10L3MBTL1HSD11B1KMT2AEPHX2 | |
| SCHEMBL12586236 | 0.75 | L3MBTL1 (0.44) | HSD17B10L3MBTL1HSD11B1KMT2AMEN1 | |
| SCHEMBL12586262 | 0.75 | HSD17B10 (0.46) | HSD17B10L3MBTL1HSD11B1KMT2AEPHX2 | |
| SCHEMBL1844609 | 0.74 | NPC1 (0.48) | NPC1POLBKMT2AMEN1 | |
| SCHEMBL5395538 | 0.72 | ALDH1A1 (0.50) | NPC1POLBKMT2AMEN1 | |
| SCHEMBL5387895 | 0.72 | ALDH1A1 (0.50) | NPC1POLBKMT2AMEN1 | |
| SCHEMBL12586479 | 0.72 | GLS (0.46) | HSD17B10L3MBTL1HSD11B1KMT2AMEN1 | |
| SCHEMBL4106867 | 0.70 | EPHX2 (0.55) | NPC1KMT2AMEN1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968601-B2 | Treating excess cortisol formation; obesity, cardiovascular disorders, glaucoma, osteoporosis, Alzheimer's Disease; antidiabetic agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-06-28 | — | — | US | disclosed |
| US-7968601-B2 | Treating excess cortisol formation; obesity, cardiovascular disorders, glaucoma, osteoporosis, Alzheimer's Disease; antidiabetic agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-06-28 | — | — | US | disclosed |
| US-20080096869-A1 | ADAMANTYL ACETAMIDES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | LINDERS JOANNES T M | 2008-04-24 | — | — | US | disclosed |
| US-20080096869-A1 | ADAMANTYL ACETAMIDES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | LINDERS JOANNES T M | 2008-04-24 | — | — | US | disclosed |
| US-7332524-B2 | Adamantyl acetamides as 11-beta hydroxysteroid dehydrogenase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-19 | — | — | US | disclosed |
| US-7332524-B2 | Adamantyl acetamides as 11-beta hydroxysteroid dehydrogenase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096869-A1 | ADAMANTYL ACETAMIDES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | DHCR7, HSD3B2, HSD3B1 | NPC1 779/4885HSD17B10 9/4885L3MBTL1 2850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.